In gynecologic cancers, bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, has regulatory approval for use across numerous indicators within advanced-stage epithelial ovarian and cervical cancers, mostly in conjunction with chemotherapy [2]. The gene discussed is VEGFA; the disease is cervical cancer.